Updates are available Correction dated 2023-04-11

Article History

Accepted: 30 January 2023

First Online: 1 March 2023

Change Date: 11 April 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40261-023-01259-6

Declarations

:

: This work was supported by Collegium Pharmaceutical. Collegium did not participate in the analysis or drafting of this manuscript. Collegium Pharmaceutical reviewed only for proprietary information.

: The RADARS System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research, and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases, and systems. All authors have no other conflicts of interest to declare.

: The protocol for the Opioid Treatment Program was originally approved on 11 May 2004 by the Institutional Review Board at the National Development and Research Institute with the most recent authorization provided on 02 March 2022 by Colorado Multiple Institutional Review Board (COMIRB). The protocol for the Survey of Key Informants' Patients Program was originally approved on 28 September 2006 by the WUSTL Human Research Protection Office, with the most recent authorization provided on 22 March 2022.

: Not applicable.

: Not applicable.

: Data are not available for release.

: Not applicable.

: JJ contributed to the study design, analysis plan, interpretation, and writing. JB contributed to the study design, analysis plan, interpretation, and writing. ME contributed to the interpretation and writing. HO conducted the analyses and contributed to the study design, analysis plan, and writing. JI contributed to the interpretation, writing, and review. RD contributed to the interpretation, writing, and review.